Recent data have demonstrated the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in the treatment of infectious diseases. A previous study used a murine model of Bordetella pertussis infection to demonstrate that treatment with the S1PR agonist AAL-R reduces pulmonary inflammation during infection. In the current study, we showed that this effect is mediated via the S1PR1 on LysM+ (myeloid) cells. Signaling via this receptor results in reduced lung inflammation and cellular recruitment as well as reduced morbidity and mortality in a neonatal mouse model of disease. Despite the fact that S1PRs are pertussis toxin-sensitive G protein-coupled receptors, the effects of AAL-R were pertussis toxin insensitive in our model. Furthermore, our data demonstrate that S1PR agonist administration may be effective at therapeutic time points. These results indicate a role for S1P signaling in B. pertussis-mediated pathology and highlight the possibility of host-targeted therapy for pertussis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853922 | PMC |
| http://dx.doi.org/10.1093/infdis/jiw536 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Sphingosine-1-Phosphate on the Facilitation of Peripheral Nerve Regeneration.
Cureus
November 2024
Division of Dental Anesthesiology, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JPN.
This study aims to explore the role of sphingosine-1-phosphate (S1P) in peripheral nerve regeneration after injury. S1P is a crucial metabolite involved in cell migration, inflammation, and nerve regeneration. In this research, six-week-old male Sprague-Dawley rats (total n=18) underwent transection of the inferior alveolar nerve (IAN) and were divided into three groups: S1PR agonist (FTY720) (n=6), saline control (n=6), and S1P1R antagonist (n=6).
View Article and Find Full Text PDFDissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P receptor-mediated G-protein activation in a mouse model of sciatic nerve injury.
Neuropharmacology
December 2024
Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. Electronic address:
Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice.
View Article and Find Full Text PDFLysophospholipid receptors in neurodegeneration and neuroprotection.
Explor Neuroprotective Ther
August 2024
Department of Biology, Winthrop University, Rock Hill, SC 29733, USA.
The central nervous system (CNS) is one of the most complex physiological systems, and treatment of CNS disorders represents an area of major medical need. One critical aspect of the CNS is its lack of regeneration, such that damage is often permanent. The damage often leads to neurodegeneration, and so strategies for neuroprotection could lead to major medical advances.
View Article and Find Full Text PDFRe-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
Front Immunol
June 2024
Synaptic Immunopathology Lab, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Roma, Rome, Italy.
Article Synopsis
- SPMS progresses from a relapsing-remitting phase and is marked by increasing disability, but lacks a reliable tool to track this transition; T cells from RRMS patients worsen neuron function, indicating synaptotoxic effects in SPMS.
- The study collected data from healthy controls and SPMS patients, analyzing the effects of siponimod on T cell interactions in brain slices and using animal models to pinpoint how siponimod helps.
- Results showed that T cells from SPMS patients increased excitatory signals in neurons compared to healthy controls, while siponimod reversed this toxicity, suggesting it could be a vital treatment strategy for managing SPMS.
The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases.
Curr Top Med Chem
November 2024
Department of Medicinal Chemistry and Centre for Marine Therapeutics (CMT), National Institute of Pharmaceutical Education and Research, Kolkata, 168, Maniktala Main Road, Kolkata, 700054, India.
Article Synopsis
- * S1PR modulators can cross the blood-brain barrier, affecting immune cells and helping to treat Multiple Sclerosis, with three currently approved medications and more under development.
- * Ongoing research is examining S1P modulators for use in neurodegenerative diseases, highlighting the need for new therapies and detailing the metabolism and effects of these molecules on the body's systems.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!